![](i_t045_s1_10-1055_s-0040-1706955.gif)

Significance
============

CoVs are the causative agents responsible for several respiratory syndromes including SARS, MERS, and COVID-19. There are no known treatments for CoV-related ailments currently. The substrate-binding site of the various CoV main proteases (M ^pro^ ) have high sequence homology and therefore represent an attractive target for the development of broad-spectrum anti-CoV therapies. In 2016, Yang and co-workers disclosed the crystal structure of the HCoV-NL63 (a human CoV) main protease (M ^Pro^ ) complexed with the covalent inhibitor N3, providing a structural basis for the pharmacological inhibition of CoV M ^pro^ that may have relevance for the ongoing SARS-CoV-2 pandemic.

Comment
=======

The M ^pro^ inhibitor N3 is a covalent inhibitor designed as an active site mimic for the TGEV M ^pro^ autoprocessing site. The crystal structure of the HCoV-NL63 M ^pro^ reveals multiple H-bond contacts between residues E166, F129, H163, G142, Q164, and S190. The α,β-unsaturated ester of N3 forms a covalent adduct with cysteine 144, validating the mechanism of inhibition of HCoV-NL63 M ^pro^ by N3. Sequence alignment of the HCoV-NL63 M ^pro^ with six related human and animal CoVs main proteases revealed that they had high sequence homology in the substrate binding site, suggesting that this class of inhibitor may serve as a lead compound for anti-Cov therapeutics.
